Meeting
2018 ASCO Annual Meeting
PEMBROSARC combination of MK3475 and metronomic cyclophosphamide (mCP) in patients (pts) with advanced sarcomas a multicentre phase II trial with 3 new combination strategies.
Authors
Maud Toulmonde
Institut Bergonié, Department of Medical Oncology, Bordeaux, France
Maud Toulmonde , Thomas Grellety , Jean-Yves Blay , Axel Le Cesne , Nicolas Penel , Sophie Piperno-Neumann , Francois Bertucci , Christine Chevreau , Emmanuelle Bompas , Sophie Cousin , Sabrina Sellan-Albert , Marina Pulido , Carine A. Bellera , Barbara Lortal , Simone Mathoulin-Pélissier , Antoine Italiano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02406781
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS11587)
DOI
10.1200/JCO.2018.36.15_suppl.TPS11587
Abstract #
TPS11587
Poster Bd #
331b
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Epacadostat plus nivolumab for advanced melanoma: Updated phase 2 results of the ECHO-204 study.
First Author: Adil Daud
Poster
2023 ASCO Annual Meeting
Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck.
First Author: Ezra E.W. Cohen
Poster
2022 ASCO Annual Meeting
CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors.
First Author: Antoine Italiano
Poster
2022 ASCO Genitourinary Cancers Symposium
Randomized phase 2 umbrella study of various neoadjuvant therapies for patients with muscle-invasive urothelial carcinoma of the bladder (MIBC) who are cisplatin-ineligible or refuse cisplatin therapy and undergoing radical cystectomy (Optimus).
First Author: Andrea Necchi